Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Head & Neck 1

Conditions

Uterine Cervical Neoplasms 5Ovarian Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 234Pemetrexed 213Paclitaxel 160Cisplatin 149pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37130-nm albumin-bound paclitaxel 35osimertinib 34Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × tisotumab vedotin × Clear all
NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

Phase 2 Completed
5 enrolled 8 charts
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT02552121 2021-04-08

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
33 enrolled 70 charts
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡